Elevance Health (ELV) Q2 2026: Revenue Growth with EPS Guidance Raise — Positive Outlook

Elevance Health, Inc. (NYSE: ELV) reported its second quarter 2026 results, showcasing a modest revenue increase and a significant raise in earnings per share (EPS) guidance. The company achieved operating revenue of $49.8 billion, reflecting an increase of $0.4 billion or +0.8% compared to the same quarter last year, where revenue was $49.4 billion.

Key Financial Metrics

• Operating Revenue: $49.8 billion (up $0.4 billion or +0.8% YoY)
• Diluted EPS: $6.71
• Adjusted Diluted EPS: $7.45
• FY 2026 Diluted EPS Guidance: Raised to at least $20.10
• FY 2026 Adjusted Diluted EPS Guidance: Raised to at least $27.00
• Operating Cash Flow: $1.9 billion
• Quarterly Dividend: $1.72 per share

Analyst View

This quarter can be viewed positively for shareholders. The revenue growth, albeit modest, indicates resilience in a challenging healthcare environment. The increase in both diluted EPS and adjusted diluted EPS, alongside the raised full-year guidance, reflects strong operational performance and management's confidence in future earnings. The company’s strategic investments aimed at lowering healthcare costs and enhancing member experiences are likely to bolster long-term growth.

Detailed Financial Analysis

• Operating Gain: The operating gain for Q2 2026 was $1.8 billion, down from $2.4 billion in Q2 2025, resulting in an operating margin of 3.5%, compared to 4.9% in the prior year. This decline is attributed to higher benefit expenses and targeted investments in workforce capabilities.
• Health Benefits Segment: Revenue in this segment reached $42.7 billion, an increase of $1.1 billion or +3% YoY. However, the operating gain decreased to $0.9 billion from $1.6 billion, reflecting increased costs.
• Carelon Segment: Carelon reported operating revenue of $19.2 billion, up $1.1 billion or +6% YoY, with an operating gain of $0.9 billion, consistent with the previous year.

Shareholder Returns and Guidance

Elevance Health declared a quarterly dividend of $1.72 per share, amounting to a total cash distribution of $373 million. The company also repurchased 0.7 million shares for $234 million at an average price of $344.62. The remaining share repurchase authorization stands at approximately $5.3 billion.

The raised guidance for FY 2026 diluted EPS to at least $20.10 and adjusted diluted EPS to at least $27.00 indicates management's confidence in achieving robust operational results moving forward. This is particularly encouraging as it suggests that the company anticipates continued growth despite current challenges in the healthcare sector.

Forward-Looking Catalysts

Investors should keep an eye on the company’s strategic investments in healthcare cost management and member experience enhancements. Additionally, the upcoming quarterly results will be crucial to assess the effectiveness of these initiatives and their impact on future earnings growth. The market will also be watching for updates on membership trends, particularly in the Medicare Advantage and Medicaid segments, as these are critical for sustaining revenue growth.

In summary, Elevance Health's Q2 2026 results reflect a solid operational performance with a positive outlook for the remainder of the year, making it a favorable scenario for shareholders.

Quarterly & Year-to-Date Consolidated Statements of Income

(In millions)

Note: The amounts in the following tables are in thousands/millions.

	Three Months Ended
	June 30, 2026	June 30, 2025
Operating Revenue	$49,800	$49,400
Operating Gain	$1,800	$2,400
Adjusted Operating Gain	$1,800	$2,500
Operating Margin	3.5%	4.9%
Adjusted Operating Margin	3.6%	5.0%

Condensed Consolidated Balance Sheet

(In millions)

	June 30, 2026	June 30, 2025
Assets
Current assets:
Cash and cash equivalents	$10,232	$9,491
Fixed maturity and equity	$27,282	$26,624
securities
Premium and other receivables	$23,392	$21,542
Other current assets	$6,278	$5,344
Total current assets	$67,184	$63,001
Long-term investments	$12,389	$11,960
Property and equipment, net	$4,645	$4,679
Goodwill and other	$39,322	$39,544
intangible assets
Other noncurrent assets	$2,898	$2,310
Total assets	$126,438	$121,494
Liabilities and equity
Liabilities:
Current liabilities:
Medical claims payable	$18,463	$17,084
Short-term borrowings	-	$150
Current portion of long-term	$375	$1,099
debt
Other current liabilities	$25,416	$22,702
Total current liabilities	$44,254	$41,035
Long-term debt, less	$30,669	$30,797
current portion
Other noncurrent liabilities	$6,493	$5,636
Total liabilities	$81,416	$77,468
Total shareholders' equity	$44,883	$43,882
Noncontrolling interests	$139	$144
Total equity	$45,022	$44,026
Total liabilities and equity	$126,438	$121,494

Disclaimer

The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.